Table 1 - Overview of drugs targeting the NP and its pathways

|  |  |  |  |
| --- | --- | --- | --- |
| Drug | Mechanism | Clinical Trials and year | Results on HF symptoms |
| Nestiride | Increasing natriuretic peptide activity | VMAC, 2000 (20)  PRECEDENT, 2002 (21)  ASCENT-HF, 2009 (22) | Improved BP and dyspnea  Less cardiac arrhythmias  More hypotension |
| Candoxatril | NPi | Uni-centre investigation with only a limited number of patients (23-25) | More exercise tolerance  Increase in vascular resistance |
| Omapatrilat | NPi | IMPRESS, 2000 (26)  OVERTURE, 2002 (27)  OCTAVE, 2004 (28) | More exercise tolerance  Increase in angioedema  Reduction in BP  Lower mortality |
| LCZ696 | NPi | PARAMOUNT, 2012 (29)  PARADIGM, 2014 (30, 31)  PARAGON, ongoing (32) | Reduction in BP  Improved ejection fraction  Lower mortality  No change in angioedema |

Abbreviation: BP: Blood Pressure; NPi: Neprilysin Inhibitors